Your browser doesn't support javascript.
loading
Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies.
Mao, Zhifeng; Álvarez-González, César; Allen-Philbey, Kimberley; De Trane, Stefania; Yildiz, Ozlem; Campion, Tom; Adams, Ashok; Turner, Benjamin P; Marta, Monica; Gnanapavan, Sharmilee; Espasandin, Maria; Mathews, Joela; Giovannoni, Gavin; Baker, David; Schmierer, Klaus.
Afiliación
  • Mao Z; Department of Neurology, Shenzhen University General Hospital, Shenzhen University, Shenzhen, China; Shenzhen University Clinical Medical Academy, Shenzhen University, Shenzhen, China; The Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, Lo
  • Álvarez-González C; The Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, United Kingdom; Clinical Board: Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, United Kingdom.
  • Allen-Philbey K; Clinical Board: Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, United Kingdom.
  • De Trane S; The Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, United Kingdom; Clinical Board: Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, United Kingdom.
  • Yildiz O; The Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, United Kingdom; Clinical Board: Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, United Kingdom.
  • Campion T; Department of Neuroradiology, The Royal London Hospital, Barts Health NHS Trust, London, United Kingdom.
  • Adams A; Department of Neuroradiology, The Royal London Hospital, Barts Health NHS Trust, London, United Kingdom.
  • Turner BP; The Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, United Kingdom; Clinical Board: Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, United Kingdom.
  • Marta M; The Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, United Kingdom; Clinical Board: Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, United Kingdom.
  • Gnanapavan S; The Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, United Kingdom; Clinical Board: Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, United Kingdom.
  • Espasandin M; The Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, United Kingdom; Clinical Board: Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, United Kingdom.
  • Mathews J; Pharmacy, The Royal London Hospital, Barts Health NHS Trust, London, United Kingdom.
  • Giovannoni G; The Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, United Kingdom; Clinical Board: Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, United Kingdom.
  • Baker D; The Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, United Kingdom.
  • Schmierer K; The Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, United Kingdom; Clinical Board: Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, United Kingdom. Electronic address: k.schmierer@qmul.ac.uk.
Mult Scler Relat Disord ; 27: 247-253, 2019 Jan.
Article en En | MEDLINE | ID: mdl-30419510
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Evaluación de Resultado en la Atención de Salud / Cladribina / Guías como Asunto / Medicina de Precisión / Factores Inmunológicos / Esclerosis Múltiple / Programas Nacionales de Salud Tipo de estudio: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Mult Scler Relat Disord Año: 2019 Tipo del documento: Article Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Evaluación de Resultado en la Atención de Salud / Cladribina / Guías como Asunto / Medicina de Precisión / Factores Inmunológicos / Esclerosis Múltiple / Programas Nacionales de Salud Tipo de estudio: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Mult Scler Relat Disord Año: 2019 Tipo del documento: Article Pais de publicación: Países Bajos